Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721460 · ClinicalTrials.gov registry record · Phase 4
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
A Phase 4 study of Parkinson's Disease and Deep Brain Stimulation Surgery, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01721460 is a Phase 4 study of Parkinson's Disease and Deep Brain Stimulation Surgery that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 6 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01721460, a Phase 4 study of Parkinson's Disease and Deep Brain Stimulation Surgery, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to find out whether dexmedetomidine changes brain cell activity in the subthalamic nucleus (STN).
Conditions Studied
Interventions
- DRUG Dexmedetomidine
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison, School of Medicine and Public Health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721460
The ClinicalTrials.gov registry entry for NCT01721460 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (99% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Dexmedetomidine is the first listed.
NCT01721460 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01721460 about?
NCT01721460 is a clinical study titled "Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus". The purpose of this research study is to find out whether dexmedetomidine changes brain cell activity in the subthalamic nucleus (STN).
What is the current status of trial NCT01721460?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2012-11. Estimated completion is 2015-06.
What conditions does trial NCT01721460 study?
This clinical trial studies the following conditions: Parkinson's Disease, Deep Brain Stimulation Surgery.
What interventions are being tested in trial NCT01721460?
The interventions under investigation include: Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT01721460?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01721460 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Validation of Dyskinesia Rating Scales
COMPLETED · Phase 4
-
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
COMPLETED · Phase 4
-
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
COMPLETED · Phase 4
-
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.